Human Growth Hormone (Somatropin / rHGH), IGF-1 & Growth-Factor Products
Human Growth Hormone (Somatropin / rHGH), IGF-1 & Growth-Factor Products is classified under Group B (Pharmacological & Prohibited Performance-Enhancing Substances). It is NOT recommended as an athletic performance aid. This monograph provides objective clinical pharmacology, toxicology, Indian statutory regulation, and WADA anti-doping education only—it never provides doping cycles, stacking regimens, or testing-evasion instructions. Any legitimate therapeutic use requires specialist medical diagnosis and supervision.
1. Generic or Accepted Substance Name & Classifications
Accepted Name: Human Growth Hormone (Somatropin / rHGH), IGF-1 & Growth-Factor Products
Common Names, Synonyms & Classifications: Somatropin IP (Recombinant Human Growth Hormone — rHGH); Mecasermin (rhIGF-1); Lonapegsomatropin; Somapacitan; AOD-9604; hGH 176-191
Section Classification: Group B — Pharmacological & Prohibited Performance-Enhancing Substances (PERF-B14)
2. Pharmacological Class
Recombinant Anterior Pituitary Polypeptide Hormone (191 Amino Acids) & Somatomedin-C (IGF-1) Axis Agonists
3. Mechanism of Action
Somatropin binds the dimeric transmembrane Growth Hormone Receptor (GHR), activating the JAK2/STAT5 pathway in hepatocytes and peripheral tissues to stimulate transcription and secretion of Insulin-like Growth Factor-1 (IGF-1), IGFBP-3, and acid-labile subunit (ALS). Promotes lipolysis, collagen/extracellular matrix turnover, and epiphysial chondrogenesis, while exerting anti-insulin (diabetogenic) hepatic gluconeogenic effects.
4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)
Pharmacological Effect: Increases lipolysis, extracellular water retention, and connective-tissue collagen synthesis. CRITICAL SCIENTIFIC REALITY: Systematic reviews of controlled trials in healthy trained athletes demonstrate that exogenous Growth Hormone increases extracellular water-retained 'lean body mass' and collagen turnover, but does NOT improve maximal isometric muscle strength, power output, or aerobic VO₂max, while significantly increasing soft-tissue oedema, carpal tunnel compression, and insulin resistance!
5. Quality of Scientific Evidence
Evidence Assessment: PROHIBITED PHARMACOLOGICAL DOPING CLASS (WADA S2.2.3 & S2.3) — Controlled trials show lack of true contractile strength/endurance benefit in healthy adults alongside severe metabolic/acromegalic toxicity
6. Approved Medical Uses (Where Applicable)
Specialist paediatric and adult endocrinology prescription indications only: Paediatric growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic renal insufficiency growth failure, and confirmed adult hypopituitarism.
7. Sports-Related Uses, Misuse Patterns & Contamination Risks
Illicit subcutaneous abuse in bodybuilding and sprinting (often co-abused with insulin or anabolic steroids), or abuse of unapproved peptide fragments (AOD-9604, hGH 176-191). Detectable via the WADA hGH Isoform Differential Immunoassay (ratio of recombinant 22-kDa isoform to pituitary isoforms) and the hGH Biomarkers Test (serum IGF-1 and P-III-NP).
8. Adverse Effects & Serious Safety Risks
Iatrogenic acromegaly (irreversible acral bone overgrowth of the jaw/mandible [prognathism], brow, hands, and feet), visceromegaly (cardiomegaly, hepatosplenomegaly), severe fluid retention/peripheral oedema, carpal tunnel syndrome, arthralgia, myalgia, insulin resistance and overt Type 2 diabetes mellitus, benign intracranial hypertension (pseudotumour cerebri), hypertrophic cardiomyopathy, and potential acceleration of occult neoplasms.
9. Contraindications & Precautions
Active malignancy (must be tumour-free before any clinical therapy), proliferative diabetic retinopathy, closed epiphyses (for linear growth indications), acute critical illness after open-heart/abdominal surgery, and non-medical athletic use.
10. Drug Interactions
Glucocorticoids inhibit the growth-promoting effects of Somatropin; Somatropin induces hepatic CYP3A4 and antagonises the hypoglycaemic effect of insulin and oral antidiabetic drugs.
11. Clinical & Laboratory Monitoring Considerations
In legitimate endocrinology care: Serum IGF-1, fasting blood glucose and HbA1c, thyroid function (free T4/TSH — unmasking of central hypothyroidism), funduscopic examination for papilloedema, and bone age radiographs in children.
12. Dependence, Misuse or Withdrawal Concerns
Psychological body-image dysmorphia and dangerous polypharmacy (co-abuse of rapid-acting insulin to counter hGH hyperglycaemia, which can cause fatal hypoglycaemic coma).
13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)
Prescription-only Schedule H biological drug under the Drugs and Cosmetics Act, 1940 and Indian Pharmacopoeia (IP 2022). Cold-chain storage (2°C–8°C) mandatory.
14. Official WADA Prohibited-List Status
PROHIBITED AT ALL TIMES (In-Competition and Out-of-Competition) under WADA Prohibited List Category S2.2.3 (Growth Hormone, its Analogues [lonapegsomatropin, somapacitan, somatrogon] and Fragments [AOD-9604, hGH 176-191]) and S2.3 (Growth Factors and Growth Factor Modulators, including IGF-1, FGFs, HGF, MGF, PDGF, TB-500, and VEGF).
15. Authoritative Source References & Date of Last Verification
Date of Last Verification: 11 November 2026